Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Canaccord Genuity

This MicroStrategy Analyst Is Slashing Their Price Target After $1B Loss, Michael Saylor Steps Down

MicroStrategy (NYSE: MSTR) recently reported a net loss of more than $1 billion in the second quarter compared with a loss of about $299.3 million in the same period last year.

Benzinga

Tesla Whale Trades For July 29

Someone with a lot of money to spend has taken a bearish stance on Tesla (NASDAQ:TSLA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Check Out What Whales Are Doing With Tesla

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's Why Accolade Shares Are Trading Higher Today

Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ:ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as the company beat management's initial outlook for FY23 revenue and adjusted EBITDA. While early in the selling season, ACCD won more new business in 1QF23 than…

Benzinga

Canaccord Genuity Maintains Buy Rating for InMode: Here's What You Need To Know

Canaccord Genuity has decided to maintain its Buy rating of InMode (NASDAQ:INMD) and lower its price target from $50.00 to $40.00. Shares of InMode are trading down 2.15% over the last 24 hours, at $22.76 per share. A move to $40.00 would account for a 75.75% increase from the current…

Benzinga

Crypto Analyst Still Bullish On Bitcoin Miners, Names 4 Top Stock Picks

Plummeting cryptocurrency prices have made life difficult for Bitcoin (CRYPTO: BTC) miners in 2022, but Canaccord Genuity analyst Joseph Vafi said Monday that he maintains his bullish long-term outlook for crypto miners Argo Blockchain ADR (NASDAQ:

Benzinga

This Snowflake Analyst Is Turning Bullish On Innovation, Valuation

Snowflake Inc’s (NYSE: SNOW) analyst day and customer conference highlighted innovations that could lead to higher consumption and better monetization, according to Canaccord Genuity.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Snowflake Stock Is Heating Up Today

Snowflake Inc (NYSE: SNOW) shares are trading higher Wednesday following bullish analyst coverage from Canaccord Genuity.

Benzinga

These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry

In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its success on the regulation and approval of scheduled psychoactive substances for mental health and other health indications.

Benzinga

Read How Analysts Reacted To MongoDB Post Q1 Earnings Beat

Analysts appreciated MongoDB, Inc's (NASDAQ:MDB) Q1 beat but cut the price target to reflect macro headwinds. Needham analyst Mike Cikos maintained MongoDB with a Buy rating and lowered the price target from $362 to $310. The price target change reflected the declines in the broader stock market. Cikos acknowledged MongoDB's strong 1QF23 feat outperforming guidance and expectations.…

Benzinga

Adam & Co strengthened by parent's latest acquisition

Deal sees the Edinburgh-based team double in size

Insider UK

Canaccord Genuity Maintains Buy Rating for Evolent Health: Here's What You Need To Know

Canaccord Genuity has decided to maintain its Buy rating of Evolent Health (NYSE:EVH) and raise its price target from $40.00 to $45.00. Shares of Evolent Health are trading down 2.43% over the last 24 hours, at $27.84 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

Benzinga

Canaccord Genuity Maintains Buy Rating for Alphabet: Here's What You Need To Know

Canaccord Genuity has decided to maintain its Buy rating of Alphabet (NASDAQ:GOOGL) and lower its price target from $3500.00 to $3300.00. Shares of Alphabet are trading down 3.63% over the last 24 hours, at $2286.75 per share.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Canaccord Genuity Maintains Buy Rating for Vapotherm, Lowers Price Target To $12

Canaccord Genuity has decided to maintain its Buy rating of Vapotherm (NYSE:VAPO) and lower its price target from $21.00 to $12.00. Shares of Vapotherm are trading down 1.52% over the last 24 hours, at $6.48 per share.

Benzinga

51 Biggest Movers From Yesterday

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales and development agreement.

Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session

Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales and development agreement.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

Upgrades

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Here's Why Canaccord Is Bullish On This Cryptocurrency Mining Company

Canaccord Genuity analyst Joseph Vafi initiated coverage of HIVE Blockchain Technologies Ltd (NASDAQ:HIVE) with a Buy rating and a $2.80 price target, suggesting an upside of 27%. Digital assets, especially Bitcoin and Ethereum, successfully exited another test of their resiliency in the face of recent market volatility. Vafi expects miners to benefit if bitcoin prices…

Benzinga

Read How Analysts Reacted To AeroVironment's Q3 Earnings Report

RBC Capital analyst Ken Herbert raised the price target on AeroVironment, Inc. (NASDAQ:AVAV) to $70 (4% downside) from $65 and maintained a Sector Perform rating on the shares after its Q3 earnings. The analyst states that while fundamentals appear to be improving for the company, the results also highlighted continued budget and supply chain risk,…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.